Access to therapy is part of the protection of the constitutional order: Peter Bely spoke at the SPIEF session on intellectual property
08.06.2022
Medicines
08.06.2022
Promomed Group of Companies has registered the drug Lenalidomide for the treatment of multiple myeloma. The antitumor drug became the fourth in the company's cancer portfolio.
Multiple myeloma is one of the most common diseases in hematology, the second most common tumor of the hematopoietic system. Until recently, it was considered a disease of the elderly, but over the past few years, the disease has been increasingly detected in people aged 45-50 years. More than 4,000 thousand cases are recorded annually in our country alone.
The drug contains the active substance lenalidomide, which affects the body's immune system and has a direct effect on tumor cells by suppressing their growth.
Forming a portfolio of medicines aimed at treating socially significant diseases, including cancer, is one of the most important tasks for Promomed Group as part of its strategy to solve global medical problems, save lives and significantly improve patient health. When introducing new drugs to the market, including generic ones, the company offers patients effective and safe medicines due to the high quality of their substances, the manufacturability of production processes, and the highest quality control standards.
Lenolidomide-Promomed will be available in capsule form with a dosage from 2.5 mg to 25 mg, which corresponds to standard application regimens.
Like most medicines produced by Promomed Group, this drug is included in the list of VED.
Get the most interesting news and publications first!
Sent successfully!
Press office
To request a press release or interview, please contact our press office
